<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069041</url>
  </required_header>
  <id_info>
    <org_study_id>15233</org_study_id>
    <secondary_id>I4T-CR-JVCQ</secondary_id>
    <nct_id>NCT02069041</nct_id>
  </id_info>
  <brief_title>A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer</brief_title>
  <official_title>Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if the advised dose of ramucirumab is safe to
      be taken with chemotherapy treatment in participants with advanced liver tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through study completion (estimated as 8 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab</measure>
    <time_frame>Baseline through Cycle 9, Day 1 (Cycle = 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of Ramucirumab</measure>
    <time_frame>Baseline through Cycle 9, Day 1 (Cycle = 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Ramucirumab Antibodies</measure>
    <time_frame>Baseline through Cycle 9, Day 1 (Cycle = 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Responses Rate (ORR)</measure>
    <time_frame>Response to disease progression or death (estimated as 2 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + FOLFOX4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles. Participants may continue to receive treatment until discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Ramucirumab + FOLFOX4</arm_group_label>
    <other_name>IMC-1121B</other_name>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX4</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Ramucirumab + FOLFOX4</arm_group_label>
    <other_name>FOLFOX4 (leucovorin + fluorouracil + oxaliplatin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of hepatocellular carcinoma (HCC) or imaging
             findings consistent with HCC in a participant with liver cirrhosis and
             alpha-fetoprotein &gt; 200 nanogram per milliliter

          -  At least 1 measurable or non-measurable lesion

          -  Child-Pugh A

          -  Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to
             locoregional therapy or refractory to locoregional therapy

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Have not received previous systemic therapy for advanced HCC

          -  Have resolution to Grade ≤1 of all clinically significant toxic effects of prior
             locoregional therapy

          -  Adequate organ function including: Absolute neutrophil coun t≥1.5×109/liter (L),
             hemoglobin ≥9 gram/deciliter, and platelets ≥90×109/L; Total bilirubin level ≤1.5 the
             upper limit of the normal range (ULN), aspartate transaminase and alanine transaminase
             ≤5 ULN, albumin &gt;28 gram/L; Serum creatinine level ≤1.5 ULN; or calculated serum
             creatinine clearance ≥50 milliliter/minute; International Normalized Ratio≤1.5 and
             partial thromboplastin time ≤5 seconds above ULN

          -  The urinary protein is ≤ 1+. If ≥ 2+ proteinuria, the 24-hour urine protein is &lt;1000
             milligram

          -  An estimated life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Received any investigational therapy or non-approved drug within 28 days prior to
             enrollment

          -  Undergone major surgery within 28 days prior to enrollment, or undergone central
             venous access device placement within 7 days prior to enrollment

          -  Undergone hepatic locoregional therapy within 28 days prior to enrollment

          -  Undergone radiation to any nonhepatic site within 14 days prior to enrollment

          -  Prior liver transplant

          -  Fibrolamellar carcinoma or cholangiocellular carcinoma

          -  Received any transfusion, blood component preparation, erythropoietin, albumin
             preparation, or granulocyte-colony stimulating factors within 14 days prior to
             enrollment

          -  Receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or
             similar agents

          -  Receiving ongoing therapy with nonsteroidal anti-inflammatory agents or other
             antiplatelet agents.

          -  Known human immunodeficiency virus infection or acquired immunodeficiency
             syndrome-related illness

          -  Active or uncontrolled clinically serious infection

          -  Uncontrolled thrombotic or hemorrhagic disorder

          -  Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to
             enrollment

          -  History of gastrointestinal perforation or obstruction

          -  History of or current hepatic encephalopathy or current clinically meaningful ascites

          -  Known allergy to monoclonal antibody, fluorouracil, oxaliplatin or their excipients

          -  Interstitial pneumonia or interstitial fibrosis of the lung

          -  Central nervous system metastases or carcinomatous meningitis

          -  Known history of dihydropyrimidine dehydrogenase deficiency

          -  Symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or
             poorly controlled cardiac arrhythmia

          -  Experienced any arterial thromboembolic event

          -  Uncontrolled arterial hypertension

          -  Grade 3-4 venous thromboembolic events occurring within 3 months prior to enrollment

          -  Experienced any grade 3-4 gastrointestinal bleeding or any variceal bleeding episode
             in the 3 months prior to enrollment requiring transfusion, endoscopic or operative
             intervention

          -  Esophageal or gastric varices that require immediate intervention or represent a high
             bleeding risk

          -  Pre-existing grade ≥ 2 motor or sensory neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 6, 2017</submitted>
    <returned>April 9, 2018</returned>
    <submitted>May 3, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

